(Total Views: 770)
Posted On: 09/27/2020 10:37:56 AM
Post# of 149028
I don’t want my appreciation of the oncoimmune success to construed as negative in regard to the prospects of leronlimab.
Cytodyn has demonstrated leronlimab efficacy in Covid through eind and CD10, with the mechanism described and demonstrated (rna transcripts pre and post leronlimab, CCR5 occupancy, macrophage repolaorization, reversal of T cell exhaustion with restoration of granzyme-A production, AND elimination of viremia).
These results, IMO, unequivocally demonstrate that immune restoration is central to successfully combatting severe Covid.
Onco-immune has found another way to modulate the immune system and resolve immune dysregulation. The world needs this.
I expect the same from leronlimab in CD12.
From Aug 4 PR reporting continuation after 149 patient safety evaluation.
“The Phase 3 study currently has 169 enrolled patients and the Company will conduct a full interim analysis once 195 patients are enrolled, as provided in the trial’s protocol.”
Let’s see what that full analysis demonstrates.
Cytodyn has demonstrated leronlimab efficacy in Covid through eind and CD10, with the mechanism described and demonstrated (rna transcripts pre and post leronlimab, CCR5 occupancy, macrophage repolaorization, reversal of T cell exhaustion with restoration of granzyme-A production, AND elimination of viremia).
These results, IMO, unequivocally demonstrate that immune restoration is central to successfully combatting severe Covid.
Onco-immune has found another way to modulate the immune system and resolve immune dysregulation. The world needs this.
I expect the same from leronlimab in CD12.
From Aug 4 PR reporting continuation after 149 patient safety evaluation.
“The Phase 3 study currently has 169 enrolled patients and the Company will conduct a full interim analysis once 195 patients are enrolled, as provided in the trial’s protocol.”
Let’s see what that full analysis demonstrates.
(7)
(0)Scroll down for more posts ▼
